Quick Answer
BioRestorative Therapies, Inc. reported Operating Income Loss of -$15.65 million for the year ending 2025.
- BioRestorative Therapies, Inc. showed a decrease of -35.4% in Operating Income Loss from 2024 to 2025.
- This data is from BioRestorative Therapies, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$1.43 million | Q2 2014: -$1.28 million | Q3 2014: -$896.0 thousand | Q1 2015: -$1.63 million | Q2 2015: -$1.26 million | Q3 2015: -$1.49 million | Q1 2016: -$2.07 million | Q2 2016: -$2.14 million | Q3 2016: -$1.72 million | Q1 2017: -$2.49 million | Q2 2017: -$2.57 million | Q3 2017: -$1.74 million | Q1 2018: -$2.23 million | Q2 2018: -$2.05 million | Q3 2018: -$1.19 million | Q1 2019: -$2.33 million | Q2 2019: -$2.13 million | Q3 2019: -$1.82 million | Q1 2020: -$819.0 thousand | Q2 2020: -$461.6 thousand | Q3 2020: -$610.3 thousand | Q1 2021: -$15.05 million | Q2 2021: -$3.56 million | Q3 2021: -$3.69 million | Q1 2022: -$5.05 million | Q2 2022: -$4.63 million | Q3 2022: -$4.61 million | Q1 2023: -$5.78 million | Q2 2023: -$3.12 million | Q3 2023: -$3.10 million | Q1 2024: -$4.11 million | Q2 2024: -$2.47 million | Q3 2024: -$2.29 million | Q1 2025: -$4.81 million | Q2 2025: -$3.31 million | Q3 2025: -$3.71 million.
- Over the full 16 years of available data (2010 to 2025), BioRestorative Therapies, Inc.'s Operating Income Loss has declined by 656.1%.
- Historical annual values: Fiscal year 2025: -$15.65 million | Fiscal year 2024: -$11.56 million | Fiscal year 2023: -$15.22 million | Fiscal year 2022: -$18.97 million | Fiscal year 2021: -$26.31 million | Fiscal year 2020: -$2.75 million | Fiscal year 2019: -$8.43 million | Fiscal year 2018: -$7.65 million | Fiscal year 2017: -$8.37 million | Fiscal year 2016: -$7.79 million | Fiscal year 2015: -$7.17 million | Fiscal year 2014: -$4.92 million | Fiscal year 2013: -$4.75 million | Fiscal year 2012: -$5.57 million | Fiscal year 2011: -$3.55 million | Fiscal year 2010: -$2.07 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: